Grant of Canadian Patent for OptiMAL
Fusion Antibodies plc has announced the grant of a Canadian patent for its OptiMAL® technology, covering two families of antibodies and their design methodology. This patent is expected to complement the Company's offering of "Opti" designed antibody libraries for applications such as antibody discovery, affinity maturation, and sequence optimisation. Fusion Antibodies is also pursuing additional patent applications for the OptiMAL® Library in other international territories, including Europe and China.
Select text to share a quote on X · sign in to keep highlights & notes in your FAB notes
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the Company's patent application no. CA 3115150 (the "Patent") has been granted by the Canadian Intellectual Property Office (the "Canadian Patent Office"). The grant of the Patent follows the receipt of a notice of allowance in respect of the Patent from the Canadian Patent Office, details of which were announced by the Company on 22 June 2026.
The Patent Application entitled "Antibody Library and Method", covers two families of antibodies, and the method for the design of such antibody libraries. The Patent is expected to be complementary to Fusion's offering to provide "Opti" designed antibody libraries for a range of applications including: Antibody Discovery; Affinity Maturation; and Sequence Optimisation.
The Company continues to progress additional patent applications in respect of the OptiMAL® Library in several other territories worldwide including Europe and China.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.